…but that’s not all! Dr. Haydar Frangoul also contributed to research published today in The New England Journal of Medicine showing the encouraging results of CRISPR/Cas9 gene-editing therapy for the treatment of Transfusion-Dependent Beta Thalassemia.
nejm.org/doi/full/10.10…

SCRI Research Leader Haydar Frangoul helped pioneer exciting research published today in NEJM showing results of CRISPR/Cas9 gene-editing therapy for the treatment of #SickleCellDisease . Read more:
nejm.org/doi/full/10.10… TriStar Health

Attention NSCLC researchers! Today Dr. Alex Spira presents his poster, 'FURVENT: A Phase 3 Trial Comparing Furmonertinib vs Chemotherapy in Advanced NSCLC with EGFR Exon 20 Insertions'. Who else is joining to discover the latest treatment options? #NSCLC #AACR2024

Join Andrew McKenzie, PhD, as he shares his insights on precision oncology in the panel discussion, 'Putting the Precision Back in Precision Oncology'. Don't miss it! #PrecisionOncology #AACR24

Dr. Meredith McKean MD, MPH has exciting news for BRAF-mutant cancers and will discuss the Phase 1 trial of PF-07799933 (ARRY-440), a next-generation BRAF inhibitor, today. Stay tuned for more insights. #BRAFmutation #AACR24

Exciting news! SCRI experts will be presenting innovative research at the AACR meeting from April 5-10 in San Diego, CA. Stay tuned for updates on their abstracts, posters, and presentations. #AACR24 #OncologyResearch #ScientificAdvancements
abstractsonline.com/pp8/#!/20272/s…

LCRF announces its 9/24 Evening of Innovation gala honoree, Dr. Mark G. Kris of Memorial Sloan Kettering Cancer Center. Dr. Kris exemplifies the spirit of LCRF to improve the lives of those with #LungCancer through research. Read about this tireless visionary & advocate: LCRF.org/gala-article

They’re SCRI physicians, of course we’re going to celebrate them on Doctors’ Day, tomorrow!
#NationalDoctorsDay #OncologyExperts

LCRF has announced 3 research grant awards funded by Daiichi Sankyo and AstraZeneca, focused on further developing the understanding of the proposed mechanism of action of antibody drug conjugates (ADCs). LCRF.org/ADC
#LungCancer Aakash Desai, MD, MPH nan.sethakorn Carl Gay, MD, PhD

The SCRI annual meeting has been a great time to connect with colleagues across the country. Excited to talk about how we move gu oncology research forward. Special shout out to Mike Lattanzi who I may call on and the other GU physicians in our network. Sarah Cannon Docs

The triplet with Cabozantinib Nivolumab and Ipilimumab may not be the new standard. But I commend the study for a modern control arm. Perhaps another triplet may bring further benefit to our patients. More work to be done and Sarah Cannon Docs will help.

Thank you Mandy Davis Aitken ! You and your team are amazing and make the meeting such a great experience.

Way to go Joshua Sabari, MD! #LCSM

Thank you @asco staff, Eric Winer, MD, SPC, Education Committee, presenters, exhibitors, and patients for a fantastic #ASCO23 🎉🎉 We have an amazing community.
See you next year at #ASCO24

Great party atmosphere ⁦Sarah Cannon Docs⁩ Karen Knudsen, MBA PhD⁩ ⁦Ishwaria Subbiah, MD MS FASCO⁩ ⁦Vivek Subbiah, MD⁩ ⁦Shaalan Beg MD MBA FASCO⁩

Dr. Danso moderated this afternoon’s #ASCO23 metastatic breast cancer session where Erika Hamilton, MD delivered exciting data on a phase 2 HER3-Dxd study Daiichi Sankyo #VirginiaOncologyAssociates

Impressive presentation by Thomas Hutson, DO, PharmD, FACP regarding updated CLEAR data Len + Pembro - it works. Kidney/Bladder Session chaired by manojkumar. Sarah Cannon Docs showing the science collaboration begins with us! The GU committee allstars are very proud:Benjamin Garmezy Mike Lattanzi Jeff Yorio, MD.

Great to catch up with Sarah Cannon Docs near and far! #ASCO23 Kathryn Hudson MD Texas Oncology manojkumar

Creating a Sustainable Oncology Workforce Through Professional Wellness ascopubs.org/doi/10.1200/AD… Sarah Cannon Docs Ishwaria Subbiah, MD MS FASCO

Proud and excited to have ⁦Ishwaria Subbiah, MD MS FASCO⁩ ⁦Vivek Subbiah, MD⁩ join our ⁦Sarah Cannon Docs⁩ team ! Already making an impact ⁦ASCO⁩